韩生物医药有限公司在2025年AACR年会上展示五种创新癌症疗法-动脉网

Hanx Biopharmaceuticals, Ltd. Showcases Five Innovative Cancer Therapies at 2025 AACR Annual Meeting

CISION 等信源发布 2025-05-07 21:30



可切换为仅中文







CHICAGO

芝加哥

，

May 7, 2025

2025年5月7日

/PRNewswire/ -- Hanx Biopharmaceuticals Ltd. (HanxBio), a clinical-stage biotechnology company pioneering next-generation immunotherapies, highlighted its expanding oncology and autoimmune disease pipeline with

/PRNewswire/ -- 汉熙生物医药有限公司（HanxBio），一家处于临床阶段、致力于下一代免疫疗法的生物技术公司，展示了其不断扩展的肿瘤学和自身免疫疾病研发管线

five research poster presentations

五张研究海报展示

at the

在

2025 American Association for Cancer Research (AACR) Annual Meeting

2025年美国癌症研究协会（AACR）年会

在

Chicago

芝加哥

(April 25–30). The presentations spotlighted novel bispecific antibodies and a CSF-1R inhibitor, underscoring the company's leadership in innovative cancer treatment strategies.

（4月25日至30日）。这些报告重点展示了新型双特异性抗体和一种CSF-1R抑制剂，凸显了该公司在创新癌症治疗策略方面的领导地位。

Key Highlights from HanxBio's AACR Presentations

HanxBio在AACR会议上展示的关键亮点

HX044

: A

：A

first-in-class (FIC) CTLA-4xSIRP

首创新药 (FIC) CTLA-4xSIRP

is a bispecific antibody fusion protein

是一种双特异性抗体融合蛋白

designed to enhance safety and amplify anti-tumor immunity. HX044 targets PD-1-resistant solid tumors (e.g., non-small cell lung cancer, melanoma, renal cell carcinoma). Currently in Phase I trials, it represents a breakthrough in overcoming resistance to existing immunotherapies.

旨在增强安全性并放大抗肿瘤免疫力。HX044 针对 PD-1 耐药的实体瘤（例如非小细胞肺癌、黑色素瘤、肾细胞癌）。目前处于 I 期临床试验，它代表了克服现有免疫疗法耐药性的突破。

HX035

: A preclinical

：临床前

OX40-targeting bispecific antibody

靶向OX40的双特异性抗体

engineered to address inflammatory and autoimmune diseases. By binding two distinct OX40 epitopes, HX035 aims to achieve best-in-class (BIC) precision in modulating immune responses.

旨在应对炎症和自身免疫疾病。通过结合两个不同的OX40表位，HX035力求在调节免疫反应方面达到同类最佳（BIC）的精准度。

HX016-7 & HX016-9

HX016-7 和 HX016-9

: Two preclinical bispecific antibodies targeting

：两种针对

PD-L1xVEGF

and

和

PD-1xVEGF

, respectively. These dual-target therapies aim to disrupt both tumor immune evasion and blood vessel growth (angiogenesis), offering a novel approach to treating solid tumors.

，分别。这些双重靶向疗法旨在破坏肿瘤的免疫逃逸和血管生长（血管生成），为治疗实体瘤提供了新的方法。

HX301 (Narazaciclib)

HX301（Narazaciclib）

: A

：A

CSF-1R inhibitor

CSF-1R抑制剂

co-developed with

与...共同开发

Traws Pharma, Inc.

特劳斯制药公司

, now in Phase II trials for glioblastoma. HX301 is being evaluated in combination with temozolomide (TMZ), a standard chemotherapy, to enhance anti-tumor efficacy.

，目前正处于胶质母细胞瘤的二期临床试验阶段。HX301正与替莫唑胺（TMZ）这一标准化疗药物联合评估，以增强抗肿瘤效果。

Dr.

博士

Henry Li

李亨利

, CEO and CSO of HanxBio, attended and presented posters

韩xBio公司的首席执行官和首席科学官出席并展示了海报。

在

the AACR Annual Conference and he emphasized the company's progress: 'Our AACR presentations reflect HanxBio's commitment to redefining cancer and autoimmune disease treatment through cutting-edge bispecific antibody platforms. With HX044 advancing in clinical trials and a robust preclinical pipeline, we are poised to deliver transformative therapies that address critical unmet needs for patients globally.' He added, 'By targeting multiple pathways simultaneously or by exploring coordinated binding (cis-bindings)—we aim to overcome enhanced activity and safety, thus improving outcomes for hard-to-treat cancers.'.

AACR年会，他强调了公司的进展：“我们在AACR的报告体现了HanxBio通过前沿的双特异性抗体平台重新定义癌症和自身免疫疾病治疗的决心。随着HX044在临床试验中的推进以及强大的临床前管线，我们准备提供满足全球患者关键未满足需求的变革性疗法。”他补充道，“通过同时靶向多条通路或探索协同结合（顺式结合），我们的目标是提升活性和安全性，从而改善难治癌症的治疗效果。”

About Hanx Biopharmaceuticals, Ltd.

关于翰思生物医药有限公司

HanxBio is an innovation-driven biotechnology company focused on discovering and developing

韩博生物是一家创新驱动的生物技术公司，专注于发现和开发

first-in-class (FIC)

首创药物 (FIC)

and

和

best-in-class (BIC)

同类最佳 (BIC)

therapies for cancer and autoimmune diseases. Leveraging expertise in structural biology, translational medicine, and precision clinical development, the company aims to create safe, accessible, and effective treatments that address global health challenges.

针对癌症和自身免疫性疾病的疗法。公司利用在结构生物学、转化医学和精准临床开发方面的专业知识，旨在创造安全、可及且有效的治疗方法，以应对全球健康挑战。

For media inquiries

媒体咨询请联系

, please contact:

，请联系：

Info@hanxbio.com

SOURCE Hanx Biopharmaceutical Co., Ltd.

源泉汉熙生物制药有限公司

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻吗？

FEATURED ON PRNEWSWIRE.COM?

刊登在PRNEWSWIRE.COM上？